1. Home
  2. DFDV vs LIXT Comparison

DFDV vs LIXT Comparison

Compare DFDV & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFDV

DeFi Development Corp.

HOLD

Current Price

$2.93

Market Cap

93.4M

Sector

Finance

ML Signal

HOLD

Logo Lixte Biotechnology Holdings Inc.

LIXT

Lixte Biotechnology Holdings Inc.

HOLD

Current Price

$7.45

Market Cap

107.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFDV
LIXT
Founded
2018
2005
Country
United States
United States
Employees
16
3
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.4M
107.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DFDV
LIXT
Price
$2.93
$7.45
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$45.00
N/A
AVG Volume (30 Days)
1.1M
412.0K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.58
N/A
Revenue Next Year
$23.65
N/A
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.44
$1.28
52 Week High
$32.00
$8.25

Technical Indicators

Market Signals
Indicator
DFDV
LIXT
Relative Strength Index (RSI) 43.41 58.00
Support Level $2.61 $3.82
Resistance Level $5.22 $7.64
Average True Range (ATR) 0.29 0.74
MACD 0.03 -0.03
Stochastic Oscillator 35.97 66.74

Price Performance

Historical Comparison
DFDV
LIXT

About DFDV DeFi Development Corp.

DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.

Share on Social Networks: